Literature DB >> 2996827

Metabolism of vitamin D in patients with primary biliary cirrhosis and alcoholic liver disease.

E B Mawer, H J Klass, T W Warnes, J L Berry.   

Abstract

The metabolism of isotopically labelled vitamin D2 and D3 has been investigated in eight patients with primary biliary cirrhosis and in five controls. The concentration of labelled vitamin D2 was lower than that of vitamin D3 in serum of patients with primary biliary cirrhosis on days 1 and 2 after intravenous injection (P less than 0.005 and P less than 0.05, respectively) but no difference was seen in controls. Similar amounts of labelled 25-hydroxyvitamin D2 and D3 were seen in serum of the control group; the same pattern was observed in the primary biliary cirrhosis group, and no significant differences were observed between the two groups. In both control and primary biliary cirrhosis groups, the serum concentration of labelled 24,25-dihydroxyvitamin D2 exceeded that of 24,25-dihydroxyvitamin D3 (significant for controls on day 2, P less than 0.02) but concentrations in the two groups were not different. Concentrations of labelled 25,26-dihydroxyvitamin D3 were significantly higher than those of 25,26-dihydroxyvitamin D2 in the primary biliary cirrhosis group at all times and in the control group on days 2 and 3. Both 25,26-dihydroxyvitamin D2 and D3 were higher in the serum of patients with primary biliary cirrhosis than in controls (significant on day 1; P less than 0.05). Urinary excretion over days 0-3 of radioactivity from both vitamins D2 and D3 was significantly higher in the primary biliary cirrhosis group than in controls: 12.03 vs 1.80% for vitamin D2 and 8.98 vs 1.76% for vitamin D3 (P less than 0.005). Vitamin D2-derived urinary radioactivity in primary biliary cirrhosis correlated strongly with serum bilirubin (P = 0.005). The metabolism of labelled vitamin D3 was studied in seven patients with alcoholic liver disease, three of whom showed low serum concentrations of labelled 25-hydroxyvitamin D3 suggesting impaired hepatic synthesis. The 25-hydroxylation response was quantified as the relative index of 25-hydroxylation and was significantly related to two other indices of liver function. It is concluded that impaired 25-hydroxylation of vitamin D may occur in alcoholic liver disease and results from hepatocellular dysfunction. Less than the predicted amounts of 1,25-dihydroxyvitamin D3 were produced in four of the seven patients with alcoholic liver disease; this defect may be attributable in part to decreased precursor 25-hydroxyvitamin D and to poor renal function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996827     DOI: 10.1042/cs0690561

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

1.  Does "hepatic osteodystrophy" differ from peri- and postmenopausal osteoporosis? A histomorphometric study.

Authors:  M S Shih; C Anderson
Journal:  Calcif Tissue Int       Date:  1987-10       Impact factor: 4.333

Review 2.  Vitamin D nutrition and bone disease in adults.

Authors:  E B Mawer; M Davies
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

3.  Prevalence of vitamin D deficiency in chronic liver disease.

Authors:  J Arteh; S Narra; S Nair
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

Review 4.  Nutrition therapy: Integral part of liver transplant care.

Authors:  Lucilene Rezende Anastácio; Maria Isabel Toulson Davisson Correia
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

5.  IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand.

Authors:  Lucia Guerra-Menéndez; Maria C Sádaba; Juan E Puche; Jose L Lavandera; Luis F de Castro; Arancha R de Gortázar; Inma Castilla-Cortázar
Journal:  J Transl Med       Date:  2013-10-25       Impact factor: 5.531

6.  Cathelicidin preserves intestinal barrier function in polymicrobial sepsis.

Authors:  Jeffery Ho; Hung Chan; Yonghao Liang; Xiaodong Liu; Lin Zhang; Qing Li; Yuchen Zhang; Judeng Zeng; Felix N Ugwu; Idy H T Ho; Wei Hu; Johnny C W Yau; Sunny H Wong; Wai Tat Wong; Lowell Ling; Chi H Cho; Richard L Gallo; Tony Gin; Gary Tse; Jun Yu; Matthew T V Chan; Czarina C H Leung; William K K Wu
Journal:  Crit Care       Date:  2020-02-10       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.